BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16891464)

  • 1. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
    Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
    Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
    Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
    Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
    Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
    Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
    Querfeld C; Rizvi MA; Kuzel TM; Guitart J; Rademaker A; Sabharwal SS; Krett NL; Rosen ST
    J Invest Dermatol; 2006 Jul; 126(7):1641-7. PubMed ID: 16645590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
    Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL.
    Rieger J; Lemke D; Maurer G; Weiler M; Frank B; Tabatabai G; Weller M; Wick W
    J Neurochem; 2008 Sep; 106(6):2436-48. PubMed ID: 18662322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
    Jian W; Yamashita H; Levitt JM; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2009 Jul; 8(7):1772-8. PubMed ID: 19509273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
    Morgillo F; Martinelli E; Troiani T; Laus G; Pepe S; Gridelli C; Ciardiello F
    Mol Cancer Ther; 2008 Jun; 7(6):1698-707. PubMed ID: 18566241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
    Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
    Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
    Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
    Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
    Spalding AC; Watson R; Davis ME; Kim AC; Lawrence TS; Ben-Josef E
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6827-33. PubMed ID: 18006785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
    Lee SH; Chen T; Zhou J; Hofmann J; Bepler G
    Clin Lung Cancer; 2010 May; 11(3):169-75. PubMed ID: 20439192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
    Dudek AZ; Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Farassati F
    Invest New Drugs; 2008 Feb; 26(1):13-24. PubMed ID: 17805485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
    Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
    Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
    Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
    Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments.
    Hanauske AR; Oberschmidt O; Hanauske-Abel H; Lahn MM; Eismann U
    Invest New Drugs; 2007 Jun; 25(3):205-10. PubMed ID: 17347872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.
    Civallero M; Cosenza M; Grisendi G; Marcheselli L; Todoerti K; Sacchi S
    Leuk Lymphoma; 2010 Apr; 51(4):671-9. PubMed ID: 20218811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
    Molè D; Gagliano T; Gentilin E; Tagliati F; Pasquali C; Ambrosio MR; Pansini G; Degli Uberti EC; Zatelli MC
    Endocr Relat Cancer; 2011 Aug; 18(4):439-50. PubMed ID: 21606156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.
    Dumstorf CA; Konicek BW; McNulty AM; Parsons SH; Furic L; Sonenberg N; Graff JR
    Mol Cancer Ther; 2010 Dec; 9(12):3158-63. PubMed ID: 20971826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.